Published in Blood on December 29, 2016
Fibrinogen and Fibrin in Hemostasis and Thrombosis. Arterioscler Thromb Vasc Biol (2017) 0.75
Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A (2010) 5.69
Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A (2007) 3.36
Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A (2006) 3.09
Thrombin generation and fibrin clot structure. Blood Rev (2007) 2.37
Pulmonary dysfunction after cardiac surgery. Chest (2002) 2.18
Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood (2008) 1.64
Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood (2014) 1.55
Dendrimer toxicity: Let's meet the challenge. Int J Pharm (2010) 1.44
Structure of fibrin: impact on clot stability. J Thromb Haemost (2007) 1.29
Anticoagulants and their reversal. Transfus Med Rev (2007) 1.18
Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood (2012) 1.14
Lung injury after cardiopulmonary bypass. Perfusion (2006) 1.11
Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc Natl Acad Sci U S A (2012) 1.05
Cationic PAMAM dendrimers aggressively initiate blood clot formation. ACS Nano (2012) 0.99
Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg (2002) 0.97
Nonenzymatic polymerization of fibrinogen by protamine sulfate. An electron microscope study. Biochim Biophys Acta (1969) 0.96
Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol (2007) 0.95
Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost (2014) 0.93
The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph. Eur J Anaesthesiol (2010) 0.90
Platelet factor 4 (CXCL4) seals blood clots by altering the structure of fibrin. J Biol Chem (2006) 0.88
Platelet factor 4 enhances fibrin fiber polymerization. Thromb Res (1987) 0.87
Effect of homo poly(L-amino acids) on fibrin assembly: role of charge and molecular weight. Biochemistry (1989) 0.87
Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann Thorac Surg (2006) 0.86
Protamine and protamine reactions. Int Anesthesiol Clin (2004) 0.86
Effects of the gene carrier polyethyleneimines on structure and function of blood components. Biomaterials (2012) 0.85
Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants. Sci Transl Med (2014) 0.85
The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg (2002) 0.85
Interaction of protamine sulfate with thrombin. Am J Hematol (1983) 0.84
Charge-related lung microvascular injury. Am Rev Respir Dis (1989) 0.83
Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood (2009) 0.82
Effects of poloxamer 188 on the assembly, structure and dissolution of fibrin clots. Thromb Haemost (1991) 0.81
Fibrinogen conformations and charge in electrolyte solutions derived from DLS and dynamic viscosity measurements. J Colloid Interface Sci (2012) 0.80
At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects. Thromb Res (1994) 0.80
Lysis of surface-localized fibrin clots by adsorbed plasminogen in the presence of tissue plasminogen activator. Biomaterials (1996) 0.79
Abnormal blood clot formation induced by temperature responsive polymers by altered fibrin polymerization and platelet binding. Biomaterials (2013) 0.78
Heparin and Protamine Titration Does Not Improve Haemostasis after Cardiac Surgery: A Prospective Randomized Study. PLoS One (2015) 0.77
Lysine-derivatized polyurethane as a clot lysing surface: conversion of adsorbed plasminogen to plasmin and clot lysis in vitro. Biomaterials (2001) 0.77
Noncardiogenic pulmonary edema immediately following rapid protamine administration. Ann Pharmacother (1999) 0.77
Noncardiogenic pulmonary edema associated with protamine administration during coronary artery bypass graft surgery. J Clin Anesth (1999) 0.77
Involvement of fibrinogen in protamine-induced pulmonary hypertension. J Surg Res (1997) 0.77
A monoclonal antibody to the fibrinogen gamma-chain alters fibrin clot structure and its properties by producing short, thin fibers arranged in bundles. J Thromb Haemost (2003) 0.76
The importance of aprotinin and pentoxifylline in preventing leukocyte sequestration and lung injury caused by protamine at the end of cardiopulmonary bypass surgery. Thorac Cardiovasc Surg (2004) 0.76
FXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen/tissue factor surfaces under flow. Blood (2015) 1.61
Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood (2014) 1.55
Polyphosphate is a novel cofactor for regulation of complement by a serpin, C1 inhibitor. Blood (2016) 0.83
Polyphosphate as modulator of hemostasis, thrombosis, and inflammation. J Thromb Haemost (2015) 0.78
Deeper understanding of carboxylase. Blood (2016) 0.75
Polyphosphate and RNA Differentially Modulate the Contact Pathway of Blood Clotting. J Biol Chem (2016) 0.75
Silica particles contribute to the procoagulant activity of DNA and polyphosphate isolated using commercial kits. Blood (2017) 0.75
A polymer therapeutic having universal heparin reversal activity: molecular design and functional mechanism. Biomacromolecules (2017) 0.75
Multiplexed silicon photonic sensor arrays enable facile characterization of coagulation protein binding to Nanodiscs with variable lipid content. J Biol Chem (2017) 0.75
Lipid Specificity of the Membrane Binding Domain of Coagulation Factor X. J Thromb Haemost (2017) 0.75
Antimicrobial Peptide-Polymer Conjugates with High Activity: Influence of Polymer Molecular Weight and Peptide Sequence on Antimicrobial Activity, Proteolysis, and Biocompatibility. ACS Appl Mater Interfaces (2017) 0.75
Diversification of polyphosphate end-labeling via bridging molecules. PLoS One (2020) 0.75